Mannkind (MNKD) Other Accumulated Expenses (2011 - 2026)
Mannkind (MNKD) reported Other Accumulated Expenses of $2.8 million for Q1 2026, down 23.58% year-over-year from $3.6 million in Q1 2025, and down 7.09% quarter-over-quarter from $3.0 million in Q4 2025.
Mannkind (MNKD) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Mannkind (MNKD) has 16 years of Other Accumulated Expenses data on file, last reported at $2.8 million in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $2.8 million, down 23.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (down 23.58% YoY), and the FY2025 annual result was $3.0 million, down 31.34% from the prior year.
- Other Accumulated Expenses eased to $2.8 million in Q1 2026 per MNKD's latest filing, from $3.0 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $5.6 million in Q2 2024 and troughed at $2.5 million in Q1 2022.
- A 5-year average of $4.0 million and a median of $4.1 million in 2025 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses surged 138.33% in 2022, then slumped 33.51% in 2025.
- A 5-year view of Other Accumulated Expenses shows it stood at $4.7 million in 2022, then advanced by 16.97% to $5.5 million in 2023, then decreased by 21.11% to $4.4 million in 2024, then tumbled by 31.34% to $3.0 million in 2025, then retreated by 7.09% to $2.8 million in 2026.
- Business Quant data shows MNKD's Other Accumulated Expenses at $2.8 million in Q1 2026, $3.0 million in Q4 2025, and $4.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.78 Mn |
| Dec 31, 2025 | 2.99 Mn |
| Sep 30, 2025 | 4.06 Mn |
| Jun 30, 2025 | 4.52 Mn |
| Mar 31, 2025 | 3.64 Mn |
| Dec 31, 2024 | 4.36 Mn |
| Sep 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 5.59 Mn |
| Mar 31, 2024 | 5.47 Mn |
| Dec 31, 2023 | 5.52 Mn |
| Sep 30, 2023 | 3.40 Mn |
| Jun 30, 2023 | 4.11 Mn |
| Mar 31, 2023 | 3.45 Mn |
| Dec 31, 2022 | 4.72 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Jun 30, 2022 | 3.33 Mn |
| Mar 31, 2022 | 2.47 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 1.56 Mn |